Search Results - "glucagon"

Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis by Xiaowen Zhang, Fei Shao, Lin Zhu, Yuyang Ze, Dalong Zhu, Yan Bi

Connect to this object online.

Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China by Zhen Feng, Zhen Feng, Wai Kei Tong, Xinyue Zhang, Zhijia Tang

Connect to this object online.

Single cell transcriptomic profiling of large intestinal enteroendocrine cells in mice - Identification of selective stimuli for insulin-like peptide-5 and glucagon-like peptide-1 co-expressing cells by Lawrence J. Billing, Pierre Larraufie, Jo Lewis, Andrew Leiter, Joyce Li, Brian Lam, Giles SH. Yeo, Deborah A. Goldspink, Richard G. Kay, Fiona M. Gribble, Frank Reimann

Connect to this object online.

Knowledge, Attitude and Practice about a Newer Class of Antidiabetic Drug (Glucagon-like peptide-1 receptor agonist) Among the Health Care Professionals of Qassim University, Saudi Arabia by Alwaleed Yousef Aldhobaib, Syed Imam ​ Rabbani, Mugahid A Mobark

Connect to this object online.

Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US by Lin J, Lingohr-Smith M, Fan T

Connect to this object online.

Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro by Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA

Connect to this object online.

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity by Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård

Connect to this object online.

KATP channel blockers control glucagon secretion by distinct mechanisms: A direct stimulation of α-cells involving a [Ca2+]c rise and an indirect inhibition mediated by somatostatin by Bilal Singh, Firas Khattab, Heeyoung Chae, Lieven Desmet, Pedro L. Herrera, Patrick Gilon

Connect to this object online.

Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials by Frederick Berro Rivera, Linnaeus Louisse A. Cruz, John Vincent Magalong, Jade Monica Marie J. Ruyeras, John Paul Aparece, Nathan Ross B. Bantayan, Kyla Lara-Breitinger, Martha Gulati

Connect to this object online.

Efectos de los agonistas del receptor de péptido similar al glucagón tipo 1 como tratamiento en pacientes con obesidad y diabetes mellitus tipo 2 by Henry Williams Mejia Zambrano

Connect to this object online.

<i>Escherichia coli</i> (Lilly) and <i>Saccharomyces cerevisiae</i> (Novo) rDNA Glucagon: An Assessment of Their Actions When Supplied Selectively to Periportal Cells in the Bivascularly Perfused Rat Liver by Lívia Bracht, Jorgete Constantin, Rosane Marina Peralta, Adelar Bracht

Connect to this object online.

Efectos de los agonistas del receptor de péptido similar al glucagón tipo 1 como tratamiento en pacientes con obesidad y diabetes mellitus tipo 2 by Henry Williams Mejia Zambrano

Connect to this object online.

Effects of a 12-Month Treatment with Glucagon-like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Oxidant and Antioxidant Biomarkers in Patients with Type 2 Diabetes by Vaia Lambadiari, John Thymis, Dimitris Kouretas, Zoi Skaperda, Fotios Tekos, Foteini Kousathana, Aikaterini Kountouri, Konstantinos Balampanis, John Parissis, Ioanna Andreadou, Maria Tsoumani, Christina Chania, Konstantinos Katogiannis, George Dimitriadis, Aristotelis Bamias, Ignatios Ikonomidis

Connect to this object online.

Glucagon-Like Peptide-1 Exerts Anti-Inflammatory Effects On Mouse Colon Smooth Muscle Cells Through The Cyclic Adenosine Monophosphate/Nuclear Factor-&kappa;B Pathway In Vitro [Corrigendum] by Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA

Connect to this object online.

The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study by Ghazwa B. Korayem, Omar A. Alshaya, Omar A. Alshaya, Omar A. Alshaya, Albandari A. Alghamdi, Shahad S. Alanazi, Renad T. Almutib, Mahdi Alsaileek, Abdulrahman Alrashidi, Nasser Aldosari, Nader Bin Sheraim, Majed S. Al Yami, Majed S. Al Yami, Majed S. Al Yami, Omar A. Almohammed, Omar A. Almohammed

Connect to this object online.

Tocopheryl quinone improves non-alcoholic steatohepatitis (NASH) associated dysmetabolism of glucose and lipids by upregulating the expression of glucagon-like peptide 1 (GLP-1) via restoring the balance of intestinal flora in rats by Tao Sun, Bing Zhang, Qing-jing Ru, Xiao-mei Chen, Bo-dong Lv

Connect to this object online.

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients by Thomas Monfeuga, Jenny Norlin, Anne Bugge, Elisabeth D. Gaalsgaard, Cesar A. Prada-Medina, Markus Latta, Sanne S. Veidal, Pia S. Petersen, Michael Feigh, Dorte Holst

Connect to this object online.

C-terminal site-specific PEGylated Exendin-4 analog: A long-acting glucagon like Peptide-1 receptor agonist, on glycemic control and beta cell function in diabetic db/db mice by Daoqi Tang, Hong Tian, Jicheng Wu, Jiaxiao Cheng, Cheng Luo, Wenbo Sai, Xiaoda Song, Xiangdong Gao, Wenbing Yao

Connect to this object online.

Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015-2020 by Joshua A. Jacobs, Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, Ambarish Pandey, Adam P. Bress

Connect to this object online.

Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study by Yen-Chieh Lee, Yen-Chieh Lee, Yaa-Hui Dong, Yaa-Hui Dong, Yaa-Hui Dong, Wei-Shun Yang, Wei-Shun Yang, Li-Chiu Wu, Jou-Wei Lin, Jou-Wei Lin, Jou-Wei Lin, Chia-Hsuin Chang, Chia-Hsuin Chang, Chia-Hsuin Chang

Connect to this object online.